FDA Grants Approval for Tacrolimus ANDA203740 by Alkem Labs
The FDA has granted approval for the ANDA203740 application for Tacrolimus submitted by Alkem Labs.
Published: August 5, 2026
Updated: August 5, 2026
Author: Humanexa Intelligence
Therapeutic area: Immunology / Transplantation
Company: Alkem Labs
Asset: Tacrolimus
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Alkem Labs
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Alkem Labs' generic Tacrolimus will intensify competition in the immunosuppressant market, potentially impacting pricing and market share for existing Tacrolimus products. Portfolio teams must evaluate the implications for their strategies and pricing models.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of Alkem Labs and competitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.